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Abstract 
The tumor suppressor protein, promyelocytic leukemia protein (PML), was originally identified in acute promyelocytic 
leukemia due to a chromosomal translocation between chromosomes 15 and 17. PML is the core component of sub‑
nuclear structures called PML nuclear bodies (PML‑NBs), which are disrupted in acute promyelocytic leukemia cells. 
PML plays important roles in cell cycle regulation, survival and apoptosis, and inactivation or down‑regulation of PML 
is frequently found in cancer cells. More than 120 proteins have been experimentally identified to physically associate 
with PML, and most of them either transiently or constitutively co‑localize with PML‑NBs. These interactions are associ‑
ated with many cellular processes, including cell cycle arrest, apoptosis, senescence, transcriptional regulation, DNA 
repair and intermediary metabolism. Importantly, PML inactivation in cancer cells can occur at the transcriptional‑, 
translational‑ or post‑translational‑ levels. However, only a few somatic mutations have been found in cancer cells. A 
better understanding of its regulation and its role in tumor suppression will provide potential therapeutic opportuni‑
ties. In this review, we discuss the role of PML in multiple tumor suppression pathways and summarize the players and 
stimuli that control PML protein expression or subcellular distribution.
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Background
In the early 1990s, groundbreaking discoveries in PML 
research attracted the attention of cancer researchers. 
The first breakthrough was the mapping of the break-
point of a reciprocal chromosomal translocation between 
chromosomes 15 and 17 involved in acute promyelocytic 
leukemia (APL) [1, 2]. The promyelocytic leukemia gene 
(PML also known as MYL, RNF71, TRIM19 and PP8675) 
was first described as a fusion partner of the retinoic acid 
receptor alpha (RARα), generating the oncogenic protein 
(PML-RARα), which is present in >98% of APL cases [3]. 
Twenty-five years of intense study on the PML protein 
from many laboratories has led to the conclusion that 
PML is a multi-faceted protein that plays pivotal roles 
in cellular events under physiological and pathological 
conditions [4–6]. These include its role in tumor suppres-
sion, anti-viral and anti-bacterial responses, inflamma-
tory responses, metabolism, aging, circadian rhythm and 
unfolded protein responses (Fig. 1) [6–9]. Understanding 
the mechanism by which PML participates in these pro-
cesses will facilitate development of therapeutic strate-
gies for the treatment of PML-related diseases. Here, we 
review the literature and highlight recent progress with a 
focus on our current understanding of the role of PML in 
tumor suppression.
PML and PML‑nuclear bodies (NBs)
The Pml gene contains nine exons and spans approxi-
mately 53 kb in the genome. Due to alternative splicing 
of its C-terminal exons, six nuclear and one cytoplasmic 
isoform have been experimentally verified. PML I is the 
longest isoform and contains 882 amino acids, while the 
shortest isoform, PML VII, has 435 amino acids [4, 10]. 
The N-terminal 418 amino acids are common to all iso-
forms and harbor several structurally conserved domains 
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that include a Really Interesting New Gene (RING) finger 
domain (R), two cysteine/histidine-rich B-Box domains 
(B1 and B2) and an α-helical coiled-coil domain (CC) 
(Fig.  2). Collectively, these domains are referred as the 
RBCC domain or the tripartite motif (TRIM) [11, 12]. 
The distinct C-terminal sequences of PML isoforms sug-
gest that there are isoform-specific functions. For exam-
ple, in response to type I interferon (IFN), PML II is 
specifically required for the induction of IFN-stimulated 
genes transcription via formation of transcriptional com-
plexes with NF-κB, STAT1 and CBP [13]. PML II and V 
can form PML NB-independent of the N terminal, RBCC 
domain [14]. A detailed review of isoform-specific func-
tions of PML was recently published by Nisole et al [10].
PML has been shown to be enriched in nuclear punc-
tate structures that are interspersed between chroma-
tin [15]. These structures have been variably named 
PML nuclear bodies (PML-NBs), Kremer bodies, ND10 
(nuclear domain 10) or POD (PML oncogenic domains) 
[15]. PML-NBs are heterogeneous and dynamic struc-
tures. The RBCC domain is essential for PML-NB for-
mation [16, 17]. The size of PML-NBs ranges from 0.1 to 
Fig. 1 Summary of PML functions in diseases. PML plays pivotal roles in the indicated conditions including anti‑inflammatory responses, metabo‑
lism, stem cell maintenance, circadian rhythms, aging and unfolded protein responses. PML protein exerts its tumor suppressive function by 
regulating the cell cycle, apoptosis, senescence, migration, angiogenesis, and DNA repair pathways
Fig. 2 A schematic diagram of PML functional domains. All PML isoforms share the same N‑terminal 418 amino acids, which contain RING (R), 
B‑Box1 (B1), B‑Box1 (B2) and coiled coil (CC) domains. Nuclear PML isoforms share the same N‑terminal 552 amino acids, which in addition to RBCC, 
contains a nuclear localization signal (NLS) and a SUMO‑interacting motif (SIM) (66) present in PML isoforms I–V. Only PMLI contains a putative 
nuclear export signal (NES) at its C‑terminus
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1.0 µm and typically there are 5–30 bodies per nucleus, 
depending on the cell types, phase of cell cycle, stress 
and nutritional condition [18]. Loss of PML results in 
a loss of PML-NBs, indicating that PML protein is an 
essential component of PML-NBs [5, 19, 20]. Two mod-
els of how PML NB formation is initiated have been 
proposed. Based on the identification of a C-terminal 
SUMO interacting motif (SIM) and the sequence require-
ment in PML for co-localization with GFP-SUMO1, it 
was proposed that the nucleation of PML NBs depends 
on PML sumoylation and non-covalent interactions of 
SUMOylated PML and PML SIM [16]. However, PML VI 
(NP_150247.2), which does not have the SIM, a mutant 
missing the SIM, or PML 3 KR, which has lost all three 
SUMOylation site, are still capable of forming nuclear 
bodies and form PML polymers [16]. An alternative 
model suggests that PML NB formation is a two-step 
process. In the first step, PML NB formation relies solely 
on reactive oxygen species (ROS)-induced PML oxida-
tion, resulting in covalent bonds between PML mono-
mers. Subsequently, a polarized SIM-SUMO-dependent 
mechanism recruits sumoylated or SIM-containing part-
ner proteins, such as DAXX, followed by an increase in 
PML NB formation [21]. The later model partly explains 
why PML 3  KR and SIM-deficient isoforms still form 
nuclear aggregates.
It has been estimated that PML functionally interacts 
with more than 160 proteins directly or indirectly [22]. 
Based on information in BIOGRID (http://www.thebi-
ogrid.org/), 120 proteins physically interact with PML, 
either transiently or constitutively, as demonstrated by 
affinity capture experiments followed by Western blot-
ting (Fig. 3). These interactions suggest the possibility of 
mutual regulation between PML and its interacting part-
ners [23–25].
The role of nuclear PML and PML‑NBs in tumor 
suppression
Five years after the discovery of the Pml gene, the tumor 
suppressive activity of PML was demonstrated in sev-
eral cancer types including breast, lung, colorectal, 
prostate and bladder cancer [26–30]. Overexpression 
of PML inhibits cell proliferation and leads to cell cycle 
arrest, senescence and apoptosis whereas Pml knockout 
cells exhibit increased proliferation and resistance to 
UV and cytokine-induced apoptosis [31–33]. Moreover, 
Pml knockout mice demonstrated elevated spontaneous 
and chemically-induced tumorigenesis [32]. These data 
suggest that PML is a tumor suppressor. PML-NBs are 
thought to function as nuclear storage sites that accu-
mulate or sequester proteins in order to release these 
proteins when required [34]. Recent studies indicated 
that PML-NBs mediate protein-protein interactions and 
functions as a platform that promotes protein post-trans-
lational modification, for example, SUMOylaiton, acety-
lation, ubiquitination and phosphorylation [35].
Several distinct mechanisms underlying PML-medi-
ated tumor suppression activity have been reported 
(Fig.  4): [1] PML sequesters proteins in PML-NBs to 
repress their functions, [2] PML recruits proteins to 
PML-NBs or mediates protein-protein interaction to 
activate their function, [3] PML-NBs serve a post-trans-
lational modification hub to regulate protein activity and 
function, [4] PML facilitates targeting of transcription 
factors and co-regulators to specific region of genome 
to control gene expression, [5] PML and PML-NBs are a 
part of complexes that regulate DNA damage repair and 
[6] PML mediates alternative lengthening of telomeres 
(ALT) to maintain genome integrity. These mechanisms 
influence important cellular pathways such as apoptosis, 
p53 stability, Akt activity and gene regulation.
Caspase 3‑dependent and ‑independent pathways 
in apoptosis
The activation of caspase 3 is a key event in apoptosis and 
is vital for the inhibition of cancer cell growth [36]. PML 
induces caspase 3 activation and mediates multiple apop-
totic pathways in response to various stimuli, including 
γ-irradiation, tumor necrosis factor α (TNFα), Fas, type I 
and II interferon (INFs), and ceramide [37, 38]. The lethal 
effects of γ-irradiation and anti-Fas antibody are attenu-
ated in Pml knockout mice and cells [38, 39], indicating 
that Pml-mediated activation of caspase 3 is essential 
for apoptosis. However, PML can also recruit BAX and 
p27KIP1 to PML-NBs and can mediate apoptosis inde-
pendently of caspase 3 activation [39]. In summary, PML 
mediates apoptosis via both caspase 3-dependent and 
-independent pathways.
Regulation of p53
The tumor suppressor p53 is an extensively studied gene 
that is important for many aspects of tumor biology [40]. 
PML is a critical regulator of p53 activity and p53-medi-
ated cellular processes, such as apoptosis, cell cycle arrest, 
DNA repair and senescence. In response to cellular stress 
and DNA damage, PML enhances p53 protein stability 
by sequestering Mdm2 in NBs [41–43]. Mdm2 is a major 
cellular p53 E3 ubiquitin ligase that destabilizes p53. The 
activated big MAP kinase 1 (BMK1) interacts with PML 
and disrupts its association with Mdm2, thereby desta-
bilizing p53 [44]. Furthermore, DNA damage promotes 
the recruitment of the DNA damage-induced kinase 
Chk2 to PML-NBs where it phosphorylates p53 at ser-
ine 20, thereby blocking the interaction between Mdm2 
and p53, and subsequently alleviating p53 degradation 
[45]. In response to DNA damage or ultraviolet-induced 
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apoptosis, the acetyltransferases CBP/p300 and the 
homeodomain-interacting protein kinase-2 (HIPK2) 
along with the tumor suppressor AXIN are recruited to 
PML NBs where CBP/p300 and HIPK2 acetylate p53 at 
K382 and phosphorylate it at Ser46, respectively [46–49]. 
Both of these modifications activate p53 transcriptional 
activity and induce cell apoptosis or senescence [18, 49]. 
By contrast, the deacetylase SIRT1 is also recruited to 
PML-NBs upon overexpression of PML or activation of 
oncogenic Ras (Ha-ras V12) and deacetylation of p53 by 
SIRT1 represses p53 transcriptional activity [50]. Thus, 
p53 can be stabilized or destabilized in PML-NB depend-
ing on the composition of the NBs. This may be cell type-
specific and dependent on the conditions used in these 
studies. In sum, PML is capable of regulating p53 protein 
abundance and activity by multiple mechanisms that 
include sequestration of Mdm2-dependent PTM of p53 
and SIRT1- dependent deacetylation of p53.
Akt pathway
Activation of Akt results in phosphorylation of numer-
ous substrates, which regulate metabolism, survival, 
migration and cell cycle progression [51]. PML inhibits 
Akt activation by sequestering Akt and recruiting pro-
tein phosphatase 2a (PP2a) to PML-NBs [52]. In PML-
NBs PP2a dephosphorylates Akt and inhibits its kinase 
activity [52]. Furthermore, PML can suppress Akt activ-
ity via the eIF4E-NBS1-PI3 K-Akt axis [53]. PML directly 
interacts with and negatively regulates elF4E activity in 
PML NBs, thereby reducing eIF4E-dependent mRNA 
export, including mRNA for NBS1, an upstream activa-
tor of the phosphoinositide-3 kinase-Akt pathway [53]. 
Fig. 3 PML interactome. Based on the data from BIOGRID (http://www.thebiogrid.org/), 120 proteins transiently or constitutively physically interact 
with PML. This has been demonstrated by affinity capture followed by Western blotting experiments. The PML‑associating proteins identified by 
high‑throughput methods are not included. The thicker of the line the more publications support the association
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PML also positively regulates PTEN (phosphatase and 
tensin homolog), a suppressor of PI3  K/Akt activation. 
Monoubiquitination of PTEN is required for its nuclear 
localization and tumor suppressor activity and deubiq-
uitination by the deubiquitinase HAUSP blocks PTEN 
nuclear localization [54]. Inactivation or loss of PML 
results in a decrease in nuclear PTEN [55]. In PC3 pros-
tate cancer cells, overexpression of PML opposes HAUSP 
deubiquitination activity. PML binds to and inhibits the 
death domain associated protein DAXX, which stabilizes 
HAUSP [55]. A recent study reported that cytoplasmic 
PML is also essential for Akt- and PP2a-dependent acti-
vation of 1,4,5-triphosphate receptor (IP [3] R) phos-
phorylation, which triggers calcium release from the 
endoplasmic reticulum to initiate apoptosis [56]. In sum-
mary, PML regulates cell proliferation and survival by 
inhibiting Akt kinase activity through PP2a, eIF4E and 
HAUSP.
Potentiation of Rb activity
The retinoblastoma protein (RB) is a potent tumor sup-
pressor through its inhibitory effect on E2F transcription 
factors hosphorylation of RB (pRB) blocks its inter-
action with E2F and promotes cell cycle progression. 
PML-NBs recruit protein phosphatase 1α (pp1a), which 
dephosphorylates RB, thereby promoting the interaction 
between RB and E2Fs and repressing E2F-driven tran-
scription and cell cycle progression [57, 58]. Oncogenic 
Ras induces PML protein expression in mouse embryonic 
fibroblasts (MEFs), which results in colocalization of RB 
to PML NBs, and hypophosphorylation of RB with subse-
quent cell senescence [59].
Transcriptional regulation by PML
PML-NBs can sequester the NF-κB subunit RelA/p65, 
and inhibit its transcriptional activity in TNFα-induced 
apoptosis [60]. A20 is a NF-κB target gene that inhibits 
Fig. 4 PML NB‑mediated tumor suppression pathways. PML NBs repress protein function by sequestration, mediating protein–protein interaction, 
or acting as a post‑translational modification hub to regulate diverse tumor suppressor pathways
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TNFα-induced apoptosis in a negative feedback fash-
ion. PML represses NF-κB-mediated A20 transcription 
by preventing NF-κB from binding to the A20 promoter 
[61]. PML can also sequester Sp1 and Nur77 to NBs and 
disrupt their binding to target promoters [62, 63]. PML 
interacts and inhibits STAT3 by inhibiting STAT3 DNA 
binding activity [64]. PML also forms complexes with 
multiple corepressors (c-Ski, N-CoR, and mSin3A) and 
histone deacetylase 1 (HDAC1), which are required for 
the tumor suppressor Mad to mediate its transcriptional 
repression [65]. Together, these studies support a model 
in which PML represses gene transcription by sequester-
ing transcription factors to PML-NBs or by associating 
with transcriptionally repressive complexes.
In contract, several mechanisms have been proposed by 
which PML positively regulates transcription. PML and 
PML-NBs recruit DAXX, which also functions as a tran-
scriptional co-repressor, thereby transcriptionally dere-
pressing DAXX target genes, such as Pax3 [66] and GRα 
target genes [67–69]. Such regulation depends on Sumo1 
conjugation of PML and a SIM (sumo interacting motif ) 
in DAXX. We have previously reported that in response 
to TNFα stimulation, PML NBs sequester HDAC7, 
reducing its association with the MMP-10 promoter, 
thereby inducing MMP-10 expression [70]. In addition, 
PML blocks degradation of the class II transactivator 
(CIITA), thereby stabilizing the protein, and promotes 
the expression of its target genes that include the class II 
major histocompatibility complex [71]. The PML II iso-
form associates with transcription factors NF-κB, STAT1 
and CREB-binding protein (CBP) to facilitate transacti-
vation complex formation and activate interferon beta 
(INFβ) and interferon-responsive gene (IRG) expression 
[13]. However, it is not known whether PML II is pre-
sent at these promoters. PML, p300 and β-catenin form 
complexes and activate the transcription of a subset of 
β-catenin responsive genes that include ARF and Siamois 
[72]. Interestingly, PML collaborates with the known 
oncoprotein c-Fos and enhances AP-1 transcriptional 
activity in a transient transfection reporter assay [73] and 
is essential for c-Jun DNA binding and transcriptional 
activation in response to UV irradiation [74]. PML is 
also required for all-trans retinoic acid (AT-RA)-induced 
transactivation of the p21WAF1/CIP1 gene [32]. Moreover, 
PML physically associates with GATA1 and GATA2, the 
master transcriptional factors of hematopoietic stem cell 
development, facilitating their transcriptional activities 
[75, 76]. In summary, PML activates gene transcription 
through sequestration of transcriptional co-repressors, 
stabilization or post-translational modification of tran-
scriptional factors, and possibly other mechanisms yet to 
be elucidated.
The role of PML in DNA damage repair
Recently it has been suggested that PML and PML-NBs 
play a critical role in DNA damage repair and ALT [77–
79]. ALT is an alternative mechanism of telomere main-
tenance in immortalized human cells and cancer cells 
that is telomerase-independent [80]. In ALT cells, PML 
co-localizes with telomeric DNA, the telomere-binding 
proteins TRF1 and TRF2 as well as proteins involved 
in DNA synthesis and recombination, such as NBS1, 
Mre11, Rad51 and Rad52 [78, 79]. By binding these pro-
teins, PML and PML-NBs play a role in DNA damage 
responses, which are is important for the maintenance of 
genomic stability and integrity in ALT cells [81].
PML also co-localizes, associates with and stabilizes 
the DNA damage response protein, TopBP1 after ion-
izing radiation (IR) [82]. Upon the induction of dou-
ble strand breaks (DSBs), NBS1, ATM, Chk2 and ATR 
facilitate biogenesis of PML-NBs [83]. The 3′ → 5′ DNA 
helicase, BLM, is an important regulator of the mainte-
nance of genomic stability and has also been shown to 
reside in PML-NBs [84]. Interestingly, loss of BLM or 
PML results in increased numbers of sister-chromatid 
exchanges (SCE). BLM, RAD51 and replication protein 
(RP)-A assemble in PML-NBs during late S/G2 phase in 
undamaged cells and again after DNA damage [85]. The 
RAD50-Mre11-NBS1 complex is implicated in the main-
tenance of telomere length in the absence of telomerase 
and plays a role in repair of DSBs, including homologous 
and non-homologous recombination repair (NJEM) [86]. 
Following IR treatment, the RAD50-Mre11-NBS1 com-
plex is co-localized in PML-NBs at sites of DSBs, suggest-
ing a role of PML in repair of DSBs [87, 88]. In summary, 
PML has multiple roles in both DNA damage repair and 
maintenance of genomic stability.
Janus‑faced role of cytoplasmic PML 
in tumorigenesis
Cytoplasmic PML has been reported to have both onco-
genic and tumor suppressive functions in different bio-
logical contexts. A cytoplasmic isoform of PML that 
contains exons 1–4, 6 and 7 and part of exon 9, was iden-
tified in plasmacytoma J558 cells [89]. This isoform of 
PML contributes to MHC class I antigen presentation, 
and enables tumors to evade the immune defense of its 
host [89]. In APL cells, the PML-RARα fusion protein 
can be cleaved after V420 or V432 of the PML protein by 
neutrophil elastase and form a truncated PML protein 
that does not have the NLS and localizes in the cytoplasm 
[90]. Mutations in PML are not common but cytoplasmic 
PML can also result from mutations. A small deletion 
(1272delAG) and a splice site mutation (IVS3-1G → A) 
in the PML gene have been identified in aggressive from 
of APL. The mutant PMLs generated are truncated and 
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do not have a nuclear localization signal (NLS) [91]. They 
localize in the cytoplasm due to a premature stop codon 
before the NLS. Cells from the APL patients are resist-
ant to retinoic acid treatments and have reduced levels of 
apoptosis and increased proliferation [90–93]. In addi-
tion, the previously described truncated PML mutant 
derived from APL mutations [91] can sequester nuclear 
PML in the cytoplasm through dimerization and inhib-
its p53 tumor suppressive functions [94]. Additionally, 
increased expression and cytoplasmic localization of 
PML was observed in a hepatocellular carcinoma [95, 
96]. However it was unclear whether the PML in this tis-
sue contained mutations. Therefore, whether cytoplasmic 
wild-type PML promotes tumorigenesis is still debatable.
Emerging evidence suggests that cytoplasmic PML 
can also have tumor suppressor functions. The M2 type 
pyruvate kinase (PKM2) is overexpressed in many can-
cers [97]. A PML mutant, which harbors an NLS muta-
tion and is constitutively cytoplasmic, interacts with and 
inhibits PKM2 activity and lactose production [98]. The 
transforming growth factor beta (TGFβ) can promote 
or suppresses tumorigenesis, depending on the cellular 
context [99]. Lin et al. reported TGFβ treatment for 24 h 
specifically induces a cytoplasmic PML isoform, which 
contains exons 1–3, 7a, 8a and 8b and lacks the NLS. 
This cytoplasmic PML isoform facilitates the assembly of 
the TβRI/TβRII/SARA/Smad2/3 complex in endosomes 
and is required for Smad2/3-dependent transcription. 
Such transcription is critical for TGFβ-mediated inhibi-
tion of cell proliferation, apoptosis and cell senescence 
[100]. Additionally, overexpression of the homeodomain 
protein TGIF results in nuclear retention of such cyto-
plasmic PML and blocks TGFβ signaling [101]. Together, 
these reports conclude that cytoplasmic PML regulates 
the TGFβ pathway to promote its tumor suppressor 
activity.
In MEFs, a fraction of PML localizes to the endoplasmic 
reticulum and to mitochondria-associated membranes 
(MAM) [56]. At these sites, PML forms a complex with 
IP [3] R, Akt and PP2a. Overexpression of a fusion pro-
tein containing the entire PML protein that was targeted 
to the outer surface of the ER in MEFs promotes apopto-
sis by stimulating calcium release. In PML−/− MEFs, Akt-
dependent phosphorylation of IP [3] R is enhanced and 
calcium release from ER is decreased, thereby impairing 
the apoptosis response to H2O2 or menadione [56]. These 
findings suggest that cytoplasmic PML possesses tumor 
suppressive activity.
Regulation of PML expression and therapeutic 
opportunities
Inactivation of PML in cancer cells occurs through mul-
tiple mechanisms [26, 102]. However, only few somatic 
mutations have been reported so other mechanisms must 
be involved [26, 102]. Studies have indicated that effects 
on PML accumulation occur are at the transcriptional 
and post-translational levels. Epigenetic regulation of 
PML expression and alternative splicing of PML mRNA 
are less well studied [35]. In many types of cancers, 
down-regulation of PML protein, but not its mRNA, is 
observed. Thus, post-transcriptional regulatory mecha-
nisms are involved [26–29]. This observation provides 
therapeutic opportunities to target cancer cells with 
the goal of restoring PML protein expression by alter-
ing PML translation, localization or post-translational 
modification.
Transcriptional and translational regulation
Several reports have suggested that inflammation-asso-
ciated cytokines enhance PML transcription. The PML 
promoter contains an IFNα/β stimulated response ele-
ment and an IFNγ binding site [103, 104]. Interferons 
(INFs) have been shown to induce senescence [105], a key 
anti-cancer mechanism. IFNs induce PML transcription 
through activation of the Janus kinase/signal transducer 
and activator of transcription (JAK/STAT) pathway [103, 
104, 106]. Tumor necrosis factor alpha (TNFα) also acti-
vates PML transcription by promoting STAT1-dependent 
transactivation of the PML promoter [107, 108]. Moreo-
ver, interleukin 6 (IL-6) enhances PML transcription via 
NF-κB and JAK-STAT pathways [109]. In summary, PML 
transcription is tightly regulated by various cytokines.
In response to K-Ras-induced cellular senescence, p53 
and its homolog p73 activate PML transcription, but this 
activation can be attenuated by Akt/PKB [110, 111]. Fur-
thermore, β-catenin and plakoglobin are capable of acti-
vating the PML promoter in a LEF/TCF-independent 
manner in p53-negative KTCTL60 renal carcinoma cells 
[72].
In addition to transcriptional regulation, PML mRNA 
translation can also be regulated. In rodent cells, onco-
genic K-Ras activates Pml mRNA translation in an 
mTOR- and eIF4E-dependent manner, presumably by 
targeting the Pml 5′-untranslated region of its mRNA 
[112]. We have recently demonstrated that the 5′-UTR 
of the human PML mRNA harbors an internal ribosome 
entrance site (IRES) that can be activated in response to 
TNFα. This IRES is conserved in most mammals except 
mouse [113].
Post‑translational regulation
In most cancers, PML protein level is down-regulated. 
However, the PML transcript level is usually compara-
ble between normal and cancerous tissue [26]. These 
observations suggest that PML protein abundance is con-
trolled post-transcriptionally. PML protein abundance 
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and its functions are regulated by multiple post-trans-
lational modifications (PTMs), including ubiquitina-
tion, SUMOylation, phosphorylation, acetylation and 
peptidyl-prolyl isomerization [114, 115] (Table 1). Recent 
evidence indicates that there is crosstalk among these 
PTMs, which adds a complex layer of regulation to the 
control of the PML protein expression/function [116].
Inhibition of the proteasome pathway restores PML 
protein expression in select cancer cell lines [26, 117]. 
This observation suggested the possibility that abnor-
mal ubiquitination and subsequent degradation of PML 
in cancer cells was involved. This prompted a search for 
the relevant E3 ligases targeting the PML protein. So 
far, at least seven E3 ligases have been identified that 
can ubiquitinate PML including RNF4, UHRF1, E6AP, 
KLHL1, KLHL20 and SIAH1/2 [118–124]. Interest-
ingly, KLHL39 (kelch-like family member 39) interacts 
with PML and disrupts the binding of KLHL20 to PML 
and blocks KLHL20-mediated ubiquitination of PML 
[125]. We have previously shown that the peptidyl-prolyl 
cis-trans isomerase Pin1 binds phosphorylated PML at 
multiple sites that include S403 and S518 and promotes 
its degradation in triple-negative MDA-MB-231 breast 
cancer cells [126]. Additionally, AT-RA promotes Pin1 
degradation and potently inhibits human triple-negative 
breast (TNB) cancer cell growth and tumor growth in 
TNB cancer animal models [127]. Moreover, the phos-
phatases SCP1, SCP2 and SCP3 dephosphorylate PML at 
S518, thereby blocking Pin1- and CDK2-dependent PML 
ubiquitination as well as KLHL20-mediated degradation 
[128]. By contrast, USP11 promotes deubiquitination and 
stabilization of PML [129].
PML is subject to SUMO1 monosumoylation on 
K490 and SUMO2/3 polysumoylation on K65 and 
K160 [118, 119]. The E3 ubiquitin ligase, RNF4, binds 
polysumoylated PML through its SIMs and promotes 
SUMOylation-dependent ubiquitination [118]. Interest-
ingly, depletion of SUMO-3 reduces the number and size 
of PML-NBs [130]. SUMOylation of PML facilitates the 
recruitment of SIM-containing partner proteins to PML-
NBs through their SIMs [21, 68]. RanBP2, SIRT1, HDAC7 
and PIAS1 have been shown to promote PML SUMOy-
laiton, while MageA, a subfamily of the melanoma anti-
gen genes, attenuates PML SUMOylation [116, 131–135]. 
Arsenic trioxide (ATO) is cytotoxic and ATO-mediated 
degradation of the PML-RARα fusion protein contributes 
to its therapeutic effect for APL patients [126, 136–138]. 
This process requires direct binding of ATO to PML pro-
tein [139] and depends on SUMOylation-dependent, 
ubiquitin-mediated degradation by RNF4 [118, 119].
Phosphorylation of PML can also modulate PML pro-
tein stability. In response to growth factors, IGF-1 or 
EGF, hypoxia, ERK2 or CDK1/2 phosphorylation of 
PML is enhanced which in turn promotes the interaction 
between phospho-PML and Pin1 [134, 140]. This inter-
action facilitates Pin1-mediated protein isomerization 
[122, 141, 142] followed by ubiquitination-mediated pro-
tein degradation. By contrast, high doses of H2O2 disrupt 
the PML and Pin1 interaction, thereby stabilizing PML 
[134, 140]. The CK2 kinase phosphorylates PML S565 
Table 1 PML post‑translational modifications, regulators and effects of these modifications on PML protein levels
PMLprotein is controlled by several post-translational modifications, including ubquitination, SUMOylation, acetylation,phosphorylation and isomerization
a  Annotated as S517 in reference due to different PML isoform
Regulators Effect on PML Target region/sites References
KLHL20 (MLN4924), SIAH, E6AP, UHRF1 Down‑regulates PML protein abundance by promoting ubiquitination [120–124]
RNF4 SUMO‑dependent [118, 119]
KLHL39, USP11 Up‑regulates PML protein by blocking ubiquitination [125, 129]
MageA, HDAC7, PIAS1, SIRT1 Regulates PML
SUMOylation
K65, K160, K490 [132–134]
K490 [116, 131]
p300 Acetylation K487, K515 [146]
SIRT1, SIRT5 De‑acetylation, increase K490SUMOylation K487 [9, 116]
Chk2 Phosphorylation S117 [45]
CDK1/2 S518 [122]
ERK2 S403, S505 [142]
CK2 (Emodin) S565a [143]
BMK1 (XMD9‑92) S8, S38 [144]
HIPK2 S403, T409 [145]
SCP1, SCP2 and SCP3 De‑phosphorylation S518 [128]
Pin1 Isomerization pS518‑P519 [122, 141, 142]
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and promotes PIAS1-mediated degradation of PML, 
although the identity of the putative ubquitin E3 ligase 
is unknown [133, 143]. Similarly, the Big MAP Kinase 1 
(BMK1) down-regulates PML protein levels by phospho-
rylating PML at S403 and T409 and promoting its degra-
dation, thereby disrupting the interaction between PML 
and Mdm2 and suppressing p53 activity [44, 144]. Unlike 
CK2, CDK1/2 or BMK1, DNA damage-activated HIPK2 
promotes PML phosphorylation at S8 and S38, resulting 
in stabilization of PML [145].
PML is also subjected to acetylation at K487 and K505 
by the protein acetyltransferase p300 [146]. Through 
screening all 18 known HDACs, we demonstrated that 
SIRT1- and SIRT5-mediate deacetylaiton of PML at K487 
which is indispensible for H2O2-induced accumulation of 
nuclear PML and NBs and cell death in HeLa cells [116]. 
Furthermore, nuclear localization of PML is essential for 
H2O2-induced cell death [116].
Accumulating evidence indicates that crosstalk 
between the PTMs controls PML function. For example, 
the interaction between the ubiquitin E3 ligase, RNF4, 
and PML ubiquitination requires PML SUMOylaiton 
by Sumo2/3 [130]. Phosphorylation of PML protein by 
CDK1/2 or ERK2 is essential for Pin1 binding and Pin1-
mediated protein isomerization [122, 141, 142]. CK2-
mediated phosphorylation promotes proteasome-and 
ubiquitination-mediated degradation of PML [143] and 
the deacetylase SIRT1 promotes PML sumoylation and 
increases PML and PML NB abundance [131]. Lastly, we 
demonstrated that acetylation at K487 and sumoylation 
at K490 in PML are mutually exclusive, suggesting a neg-
ative crosstalk between these two modification [116].
Mechanisms underlying nucleocytoplasmic 
shuttling of PML
All nuclear PML isoforms harbor an NLS. Disruption of 
the NLS by mutation at K487 results in accumulation 
of PML in the cytoplasm [9, 116, 147]. In addition, the 
longest isoform, PMLI, also contains a C-terminal puta-
tive NES (Fig. 2). An early study suggested that this NES 
is functional, but inefficient [148]. Currently, the mecha-
nism by which the C-terminal NES regulates nucleocyto-
plasmic trafficking of PML1 and how the activity of the 
NES is regulated remain unknown.
In most studies, PML is localized both in the nucleus 
and cytoplasm. This can involve active re-distribution of 
PML. For example, in response to high doses of H2O2, 
SIRT1 and PML move from the cytoplasm to the nucleus 
and promote cell death in HeLa cells [116]. The HDAC 
catalytic activity of SIRT1 is essential for this H2O2-
induced accumulation of nuclear PML. Because SIRT1 
promotes deacetylation of PML at K487, a residue lying 
in the center of NLS, acetylation of K487 may influence 
PML nuclear localization by blocking recognition of the 
NLS by importins.
Recently, we discovered that oxidative stress and anti-
oxidants control the subcellular distribution of PML. 
The antioxidant sulforaphane (SFN) is a potent inducer 
of cytoprotective genes [149]. The precursor of SFN, 
glucoraphanin, is abundant in cruciferous vegetables 
with its highest concentration found in broccoli [150]. 
Recent studies indicate that SFN induces apoptosis in 
cancer cells, inhibits cancer cell proliferation [151] and 
suppresses tumorigenesis in various mouse models of 
cancer [152]. We have recently demonstrated that PML 
is essential for SFN-mediated inhibition of capillary tube 
formation and migration of endothelial cells [147]. Nota-
bly, SFN induces an accumulation of cytoplasmic PML 
and a reduction in nuclear PML, although the underly-
ing mechanism has not been elucidated. The role of PML 
nucleocytoplasmic trafficking in cellular activity remains 
an intriguing issue to address.
Conclusion and perspective
One key direction for future study will be the role of PML 
in epigenetics and chromatin organization. Many his-
tone modifying enzymes and enzymatic components of 
chromatin remodeling complexes interact with PML. For 
example, protein acetyltransferase (p300), deacetylase 
(HDAC1, HDAC2, HDAC3, HDAC7, SIRT1 and SIRT5) 
[65, 70, 116, 153, 154], methyltransferases (SETDB1 and 
SUV39H1) [155, 156], component of polycomb repres-
sive complex (EZH2) [157], and epigenetic regulator 
UHRF1 physically associate with PML [120]. However, 
little is known about whether PML controls the activity 
of these chromatin regulators. Understanding the epige-
netic regulation by PML is a pivotal step toward elucidat-
ing the mechanism of tumor suppression by PML and is 
reactivating PML in cancer cells. Currently, γ-irradiation 
and chemical therapies IFN and IL6, have been shown 
to stimulate accumulation of PML protein [49, 103, 104, 
109]. PML protein abundance is also regulated by syn-
thetic molecules, including MLN4924 (target KLHL20), 
emodin (target CK2), XMD8-92 (target BMK1) and TSA 
(HDAC inhibitor), as well as other nature compounds, 
such as H2O2, EGF, SFN, MG132, As2O3 and DNA dam-
age regents [21, 115, 147, 158]. It will be informative to 
see whether combinatorial treatment with these reagents 
enhances potency of their anti-cancer activity by syner-
gistically increasing PML protein accumulation.
In addition to its anti-proliferative and pro-apoptotic 
activity in tumor cells, PML can also influence the tumor 
microenvironment. PML inhibits neoangiogenesis, in 
part, by repressing translation of hypoxia-inducible fac-
tor 1 alpha (HIF-1α) through inhibition of mammalian 
target of rapamycin (mTOR) [159]. PML is essential for 
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the TNFα- and IFNα-mediated inhibition of angiogen-
esis in ECs through repression of integrin beta1 (ITGB1) 
expression [108]. The anti-oxidant sulforaphane (SFN)-
mediated anti-angiogenesis effects also requires PML 
protein [147]. Taken together, these findings suggest the 
suppressive function of PML in angiogenesis.
Finally, studies from Pandolfi’s group suggested that 
PML has an oncogenic function in chronic myeloid leu-
kemia due to its importance in the maintenance of hemat-
opoietic stem cells [160]. The same group also reported 
that PML is overexpressed in TNB cancer patients and 
suggested that PML is an oncoprotein in TNB [161]. In 
Pml−/− mice, the neural progenitor cells are increased and 
the transition between two progenitor types, radial glial 
cells and basal progenitors, is disrupted [57]. These data 
suggest a role for PML in brain development. Interest-
ingly, the number and size of PML NBs are significantly 
increased during glioblastoma stem cell differentiation 
[162]. However, it was recently demonstrated that Notch/
Hey1 transcriptionally represses the expression of the 
PML deubiquitinase USP11, thereby down-regulating 
PML protein levels. In glioma patients, up-regulation of 
Hey1 correlates with down-regulation of USP11 and PML 
and with glioblastoma multiforme, a grade IV glioma 
[129]. Moreover, Hey1 overexpression or USP11 depletion 
blocks the anti-proliferation/migration/invasion effects 
of wild type PML but not a USP11-resistant PML mutant 
[129]. These observations suggest an inhibitory role of 
PML in the pathogenesis of GMB. Our lab recently dem-
onstrated that Pml KO mice exhibited increased fatty acid 
oxidation in liver, which may contribute to a reduced inci-
dence of Western diet-induced dysplastic hepatic nodules 
[163]. How PML may switch from a tumor suppressor in 
one tissue to an oncoprotein in another tissue is an out-
standing question and warrants further investigation.
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